Core Insights - The Ministry of Industry and Information Technology has announced the first batch of "Biomanufacturing Pilot Capability Construction Platform List," with Huaxi Biological Technology (Tianjin) Co., Ltd. being awarded the highest "five-star" rating for its leading synthetic biology pilot platform [1][5] - Huaxi Biological is one of only five companies in the country to receive this top certification, highlighting its technological strength in the fields of cosmetics, food additives, and biopharmaceuticals [1][5] - The "five-star" certification brings attention to the critical infrastructure of pilot platforms in biomanufacturing, which is essential for bridging the gap between scientific research and industrial application [1][5] Industry Challenges and Solutions - The "valley of death" in biomanufacturing represents the significant challenge of transitioning research outcomes from the laboratory to market application, with China's technology transfer rate at only about 10% compared to 75% in developed countries [2][5] - Pilot testing is identified as a crucial step in overcoming this challenge, as it scales laboratory results from milligram to kilogram and ton levels, ensuring quality control, cost accounting, and safety verification [2][3] Huaxi Biological's Pilot Platform - Huaxi Biological has invested over 3 billion yuan to create the world's largest synthetic biology pilot transformation platform, covering 40,000 square meters and equipped with 64 pilot production lines [3][4] - The platform operates as a "biological foundry" and "debugging center," enabling year-round, green, and controllable industrial manufacturing by optimizing metabolic pathways through gene editing [3][4] - The intelligent central control system allows for real-time monitoring of thousands of indicators, enhancing predictability and control over complex biological processes [3][4] Flexibility and Cost Efficiency - The platform's modular and standardized design allows for rapid reconfiguration of production lines to meet diverse bioproduct testing needs, significantly improving equipment utilization and response speed [4] - A case study of Tianjin Zhonghe Gene Technology Co., Ltd. illustrates the platform's effectiveness, as it completed process scaling tests in one month at a 90% cost reduction compared to building its own pilot line [4] National Strategy and Industry Impact - The recognition of Huaxi Biological reflects the national strategy to develop biomanufacturing as a strategic emerging industry, with plans to cultivate over 20 pilot platforms by 2027 [5][6] - The global biomanufacturing market is projected to exceed $390 billion by 2030, positioning biomanufacturing as a key area of technological and industrial competition [5][6] - Huaxi Biological's platform serves as a public infrastructure for the industry, facilitating collaboration with universities, research institutions, and biotech startups, thus breaking down barriers between technology and industry [5][6]

本报讯 （记者冯思婕）近日，工业和信息化部、国家发展改革委联合公示全国首批生物制造中试能力建设平台名单，全国 共有43家单位入选。由传化集团有限公司（以下简称"传化集团"）与国有资本合作建设运营的"杭州合成生物产业中试（验 证）中心"成功入选，成为浙江省代表性平台之一。这标志着传化集团在合成生物产业领域的技术实力与产业化能力获得国家 级权威认可。 名单公示/官网截图 | 中华人民共和国工业和信息化部 | ry and Information Technology of the People's Republic of China | | | | ● 阳光小信 无障碍 手机端 邮箱 请输入关键字 | | --- | --- | --- | --- | --- | --- | | (2 | 首页 组织机构 | 新闻发布 | 政务公开 | 政务服务 | 互动交流 T1 | | 首页 > 工业和信息化部 > 机关司局 > 消费品工业司 > 食品 | | | 4-1660 4:1 ) 446 -- 1 | | | | 序号 | 所在单位名称 | 主要服务领域 | 地址 | 联系电话 | 电子邮箱 | 用 | | --- ...

Core Insights - The article discusses the rapid development and investment in the biomanufacturing sector in China, highlighting various projects and initiatives aimed at establishing mid-test platforms across multiple regions [5][6][12]. Investment and Project Developments - In Chongqing, a total of 32 projects with an investment of 14.53 billion yuan were signed, focusing on biomanufacturing, biomedicine, and other high-tech industries [5]. - The Chongqing Biomanufacturing Industry Pilot Platform aims to create a national-level mid-test platform for biomanufacturing, emphasizing intelligent biological fermentation and related technologies [6]. - The platform is part of a broader initiative that includes 1,252 key projects with a total investment of approximately 3.2 trillion yuan planned for 2025 [6]. Regional Initiatives - Changde Economic Development Zone is also advancing its synthetic biomanufacturing mid-test conversion platform, with significant construction progress reported [7][8]. - The Changde platform has a total investment of 169 million yuan and will feature multiple mid-test production lines to cater to various scales and types of biomanufacturing [8]. National Support and Policy Framework - Multiple provinces, including Guangdong, Shanghai, and Sichuan, are actively supporting the establishment of mid-test platforms, with specific funding and policy frameworks in place [10][11][12]. - The Ministry of Industry and Information Technology and the National Development and Reform Commission have set a goal to cultivate over 20 mid-test capability construction platforms by 2027, aiming to serve more than 200 enterprises [12].